Cell-permeable peptide inhibitors of the JNK signal transduction pathway
The invention provides cell-permeable peptides that bind to JNK proteins and inhibit JNK-mediated effects in JNK-expressed cells.
1. A chimeric peptide capable of inhibiting the activation of at least one c-jun amino terminal kinase (JNK) signaling pathway, said chimeric peptide being 35 amino acids or less in length, comprising a first domain and a second domain linked by a covalent bond at either the N-terminal or the C-terminal end of the first domain, wherein the first domain comprises the amino acid sequence of SEQ ID NO: 8, and the second domain comprises a JNK inhibitor sequence selected from the group consisting of
a) a peptide with the amino acid sequence of SEQ ID NO:3 and
b) a peptide having at least 80% sequence identity to SEQ ID NO:3,
wherein the JNK inhibitor sequence is capable of inhibiting the activation of at least one JNK signaling pathway.
2. The chimeric peptide of claim 1 , wherein the first domain augments cellular uptake of the peptide.
3. The chimeric peptide of claim 1 , wherein the first domain directs nuclear localization of the peptide.
4. The chimeric peptide of claim 1 , wherein the JNK inhibitor sequence binds c-Jun amino terminal kinase (JNK).
5. The chimeric peptide of claim 1 , wherein the JNK signaling pathway comprises at least one transcription factor selected from the group consisting of c-Jun, ATF2, and Elk 1.
6. A peptide consisting of the amino acid sequence of SEQ ID NO:3.
7. A pharmaceutical composition comprising the chimeric peptide of any of claims 1 - 5 and a pharmaceutically acceptable carrier.